We have recently shown that CD30, a member ofthe tumor necrosis factor/nerve growth factor receptor superfamily, is preferentially expressed by human T cell clones producing T helper (Th) type 2 cytokines . We report here that costimulation with an agonistic anti-CD30 monoclonal antibody enhanced antigen (Ag)-induced proliferation and cytokine secretion by established human Th2 and Th0 clones. Moreover, costimulation of peripheral blood mononuclear cells with the same anti-CD30 monoclonal antibody resulted in the preferential development ofAg-specific T cell lines and clones showing a Th2-like profile of cytokine secretion. In contrast, early blockade in bulk culture ofCD301igand-CD30 interaction shifted the development of Ag-specific T cells towards the opposite (Th1-like) phenotype . Taken together, these data suggest that CD30 triggering ofactivated Th cells by CD30 ligand-expressing Ag-presenting cells may represent an important costimulatory signaling for the development of Th2-type responses.
D4+ T cells can be separated both functionally and based on the cytokines they produce in response to Ag (1) . Thl cells secrete IL-2, TNF-R, and IFN-y, and, because of the macrophage-activating property of IFN-'Y, they are the principal effectors of cell-mediated immunity against intracellular microbes as well as of delayed-type hypersensitivity reactions (2, 3) . However, Th2 cells produce IL-4, IL-5, and IL-10, which promote production of antibodies (including IgE), differentiation, and activation of eosinophils, and inhibit several macrophage functions . Th2 cells mainly develop in response to helminths as well as to common environmental allergens (4, 5) .
Several studies in both murine and human models have clearly shown that the development ofboth naive and memory CD4+ T cells into the Th1 or Th2 functional phenotype is mainly regulated by cytokines (6, 7). IL-4 induces Th to differentiate into IL-4-producing cells and diminishes their priming for IFN --y production, thus polarizing the response toward the Th2 state (7, 8); IL-12 strikingly enhances priming for IFN-y production, and, through the production of IFN-y by T cells and NK cells, IL-12 diminishes priming for IL-4 production, thus polarizing the response toward a Th1 state (9, 10). However, these findings do not fully and directly explain which features of a natural or intentional immunization elicit the distinctive production of the inducing cytokines or other possible factors that may determine the phenotype ofcytokine-producing Th cells .
Recently, we have shown that CD30, a member ofTNF receptor superfamily (11) , is preferentially expressed by Th2-type CD4+ T cell clones (12) as well as by CD8+ T cell clones showing a Th2-like profile ofcytokine secretion (13) . The natural ligand for CD30 (CD30L)' has been cloned (14) , and it has been found to be expressed by B lymphocytes (15) as well as by a subset of activated macrophages and T cells (16) . We have therefore addressed the question of whether costimulation of CD30 had any functional role in the Ag-induced response of established Th2 clones as well as in the in vitro development and/or maturation of Th2 cells . Results showed that CD30 costimulation potentiated both Ag-induced proliferative response and cytokine production by established Th2 and Th0 clones. More importantly, CD30 costimulation favored the in vitro development of Ag-specific T cells toward the Th2-like profile, whereas blockade of CD30L-CD30 interaction had an inhibitory effect on the development of Ag-specific memory T cells into the Th2-like phenotype . Thus, CD30 triggering on Ag-reactive T cells by APC expressing CD30L may provide a critical costimulatory signal for the development ofTh2 responses . ' Abbreviations used in this paper: CD30-Fc, soluble form of CD30 fused to the Fc region of human IgG1 ; CD30L, natural ligand for CD30 ; Lol p I, Lolium perenne group 1; TES, excretory-secretory Ag of Toxocara canis; TT, tetanus toxoid .
Materials and Methods
Reagents . Excretory-secretory Ag of Toxocara cams (TES) was purchased by Biokema (Lausanne, Switzerland), tetanus toxoid (TT) was kindly provided by Istituto Sieroterapico e Vaccinogeno Sclavo (Siena, Italy), and purified Lolium perenne group I (Lol p I) allergen was a gift from Dr . A. A. Ansari (Johns Hopkins University, Baltimore, MD). Recombinant human IL-2 was a kind gift from Eurocetus (Milano, Italy), and recombinant human IL-5 was purchased from Amgen Biologicals (Thousand Oaks, CA). PHA was purchased from Gibco Laboratories (Grand Island, NY). Anti-CD3, anti-CD4, and anti-CD8 mAb were purchased from Ortho Pharmaceuticals (Raritan, NJ). Anti-CD30 mAb (Ber-H2) was purchased from Dako (Glostrup, Denmark) . Anti-CD30 agonist M44 mAb, anti-CD30L M81 mAb, and the soluble form of CD30 fused to the Fc region of human IgG1 (CD30-Fc) were prepared by Immunex (Seattle, WA). Polyclonal rabbit anti-human IL-4 was purchased from Genzyme Corp . (Cambridge, MA).
Generation of T Cell Lines and Clones . PBMC were obtained either from healthy volunteers who had been vaccinated with TT and showed a lymphoproliferative response in vitro to TES or from atopic grass-sensitive subjects showing immediate skin reactivity to Lol p I allergen . Ag-specific T cell lines were generated as previously described (17) . Briefly, PBMC prepared by density gradient centrifugation were resuspended (106 in 2 ml) in RPMI 1640 medium supplemented with 2 MM L-glutamine, 2 X 10 -5 M 2-ME, and 5% heat-inactivated human serum (complete medium) and stimulated with TES, Lol p 1 (2 Ft, g/ml), or TT (0.5 ltg/ ml) in 24-well plates for 6 d in the presence of immobilized anti-CD30 agonist M44 mAb (10 Rg/ml) or isotype control (murine IgG1), soluble anti-CD30L M81 mAb (5 Rg/ml) or its isotype control (murine IgG2b), and soluble CD30-Fc (1 N,g/ml) or its control (human IgGl) . After 6 d IL-2 was added (20 U/ml), and cultures were continued for an additional 5 d. Ag specificity was assessed by measuring [3 H]TdR uptake after 60 h of stimulation with the appropriate Ag in the presence of irradiated autologous non-T cells as APC, as reported (17) . To generate T cell clones, T cell blasts obtained from the different T cell lines were seeded under limiting dilution conditions (0 .3 cells per well) in roundbottomed microwell plates containing 105 irradiated PBMC (as feeder cells), PHA (0 .5% vol/vol), and IL-2 (20 U/ml), as reported elsewhere in detail (17) . Cell surface marker analysis of T cell clones was performed on a cytofluorimeter (Cytoron Absolute ; Ortho Pharmaceuticals), and Ag specificity was assessed by measuring [3H]TdR uptake after 60 h of stimulation with the appropriate Ag, as reported (17) .
Characterization of the Cytokine Profile of T Cell Lines and Clones .
To induce cytokine production by T cell lines or clones in response to their specific Ag, 106 T cell blasts were cocultured in 1 ml complete medium with 5 X 105 irradiated autologous APC and the specific Ag (0 .5-2 Rg/ml) (17) . After 48 h, culture supernatants were collected, filtered, and stored in aliquots at -70°C until used . To induce cytokine production in response to PHA, T cell blasts were resuspended at 106/ml complete medium and cultured in the presence of PHA (l % vol/vol) . After 36 h, culture supernatants were collected, filtered, and stored in aliquots at -70°C until used . Supernatants were assayed for IFN-y, TNF-[3, IL-4, and IL-5 content. The quantitative determinations of IFN-y or TNF-[3 and IL-4 were performed by commercial assays (BioSource International, Camarillo, CA ; or Quantikine, R&D Systems, Minneapolis, MN, respectively) . For the measurement of IL-5, the murine LyH7 .B13 cell line was used as source of indicator cells, as detailed elsewhere (17) . Supernatants showing IFN-y, TNF-[3, IL-4, or IL-5 levels 5 SD over the mean levels in control supernatants derived from irradiated feeder cells alone were regarded as positive . T cell clones able to produce IFN-y and TNF-(3, but not IL-4 or IL-5, were categorized as Thl; clones able to produce IL-4 and/or IL-5, but not IFN-y and/or TNF-R, were categorized as Th2; and clones producingboth IFN-y (and/or TNF-(3) and IL-4 or IL-5 were categorized as ThO.
Results

CD30 Costimulation Enhances Ag-induced Proliferation and
Cytokine Production by Established CD4+CD30+ T Cell Clones . We first investigated the responsiveness of a panel of CD30+ and CD30 -CD4+ T cell clones either to stimulation with an anti-CD30 agonist (M44) mAb or to costimulation with M44 mAb and the specific Ag . To this end, six Thl, six ThO, and six Th2 clones (whose mean CD30 expression was < 10, 14-56, and 41-87%, respectively) were cultured for 3 d in the presence of immobilized M44 alone or M44 plus Agprimed autologous APC, and their proliferative response was assessed. No response to M44 mAb was seen in the absence of Ag-primed APC stimulation (data not shown) ; however, Ag-driven proliferation was significantly increased by M44 mAb (P <0 .01) in both ThO and Th2 (CD30+) but not in Thl (CD30-) T cell clones (Table 1) . To ascertain whether the costimulatory activity of immobilized anti-CD30 might be ascribed to CD30 cross-linking, Ag-induced proliferation of two Thl, two ThO, and two Th2 clones was assessed in microplates coated with graded concentrations of M44 mAb or in the presence of soluble M44 followed by a polyclonal rabbit anti-mouse Ig Ab . As shown in Table 2 , the CD30-mediated Development of Th2 Cells T cell clones specific for TT, Lol p I, or TES were stimulated for 36 h with PHA, and cell-free supernatants were assayed for their IL-4, IL-5, and IFN-y content as reported (17) . Six Thl, six ThO, and six Th2 CD4+ clones, whose T cell blasts showed membrane CD30 expression of <10, from 14 to 56, and from 41 to 87%, respectively, were costimulated with insoluble M44 (10 wg/ml) or its isotype control in the presence of autologous APC and the specific Ag (TT, 0 .5 ltg/ml ; TES or Lol p I, 2 jig/ml) as described. 16 .1 ± 6.6 Table 2 . Costimulatory Activity ofAnti-CD30 Agonistic M.44 mAb Is Due to CD30 Cross-linking costimulatory effect of immobilized M44 mAb on Aginduced proliferation of both ThO and Th2 clones was dose dependent and was substantially inhibited by the addition of CD30-Fc. In the same experiment, costimulation of Aginduced proliferation was also induced by soluble M44 followed by a polyclonal rabbit anti-mouse Ig Ab, suggesting that the activity of the agonist anti-CD30 mAb could be ascribed to CD30 cross-linking . We then asked whether costimulation of T cell clones with insoluble M44 mAb could also influence their ability to produce cytokines. To answer this question, IFN-y, IL-4, and IL-5 production was measured in culture supernatants of the same Thl, ThO, and Th2 clones cultured for 48 h in the presence of M44 mAb (or its isotype control), with or without the addition of Agprimed APC. Stimulation with M44 mAb alone did not result in the production of any detectable cytokine, whereas costimulation with M44 mAb, but not with isotype control, significantly increased both IL-4 and IL-5 Ag-induced production in all Th2 clones (P <0 .001) and, to an even lower extent, in all ThO clones (P <0.05)_ Under the same conditions, M44 mAb also significantly enhanced Ag-induced IFN-y production by ThO clones (P <0 .05), but it had virtually no effect on IFN-y production by Thl clones ( stimulating their PBMC with specific Ag in the absence or presence of insolubilized M44 mAb or of its isotype control. As shown in Fig. 2 A, in the series of 108 CD4+ T cell clones derived from M44 mAb-costimulated lines, the proportion of clones able to produce Th2-type cytokines (IL-4 and IL-5) was significantly increased, whereas the propor- Figure 2 . Costimulation with anti-CD30 agonist M44 mAb favors the preferential expansion of T cells producing Th2-type cytokines . Two series of TT-specific T cell lines were raised in the presence of insoluble M44 or its isotype control, as described in Table 1 tion of clones producing Thl-type cytokines (IFN-y and/ or TNF-(3) was significantly reduced in comparison with those found in the 90 clones derived from TT-specific lines costimulated with isotype control . When the two series of TT-specific clones were compared for the distribution of cytokine profiles, a significant reduction of Thl (14 vs 43%) and an increase ofboth Th0 (67 vs 50%) and Th2 (19 vs 7%) phenotypes were found in the series costimulated with M44 mAb (Fig. 2 B) . These data suggest that costimulation via CD30 favored the preferential development and/or the selective growth of Th cells able to produce Th2-type cytokines.
Blockade of CD30-CD30L Interaction Results in the Outgrowth of Ag-specific T Cell Lines and Clones Able to Produce Thl-Type Cytokines and Inhibits the Development of Th2-like T Cells. In view ofthe effects ofanti-CD30 agonist mAb, we asked whether blockade of the interaction between CD30 and its natural ligand (CD30L) could also influence the cytokine secretion profile ofAg-specific T cells . To this end, Lol p I-specific T cell clones were generated from three different donors by stimulating their PBMC with Lol p I alone or Lol p I plus anti-CD30L mAb (M81), CD30-Fc fusion protein, or anti-IL-4 Ab. As expected, among the 84 CD4 + T cell clones generated in presence of anti-IL-4 Ab, the proportion of those showing a Thl-like profile was remarkably increased with concomitant reduction of Th2-like clones in comparison with the 86 CD4 + T cell clones derived from Lol p I stimulated in presence of nonimmune rabbit Ig (Fig. 3) . Likewise, either in the series of 101 CD4 + T cell clones derived from anti-CD30L mAbconditioned cells or in the series of 99 clones derived from CD30-Fc-treated cells, the proportions of clones able to produce IL-4 and IL-5 were significantly reduced, whereas the proportion of clones producing IFN-y was significantly increased in comparison with that found in the 86 Lol p I-specific control clones. When the different series ofclones were compared for their distribution of cytokine profiles, a significant increase of Thl (34 and 31 vs 15%) and a decrease of Th2 (29 and 37 vs 58%) phenotypes were found in the series derived from cells conditioned with either anti-CD30L mAb or CD30-Fc (Fig. 3) .
We finally asked whether blockade of CD30L-CD30 interaction was effective only in the early phases of T cell activation by Ag, or whether it could still influence the cytokine secretion profile of Ag-specific T cells if applied later. To this end, the effects ofanti-CD30L M81 mAb and CD30-Fc were assessed in kinetics experiments in which the two reagents were added at different time intervals , pooled routine and rabbit control Ig (10 p,g/ml), CD30-Fc (1 p g/ml), or rabbit polyclonal anti-IL-4 Ab (10 p .g/ml) . T cell blasts from each T cell line were cloned as detailed in Table 1 . A total of 101 Lol p I-specific CD4 + clones generated in the presence of M81 mAb, 86 Lol p I-specific CD4 + clones generated in the presence of control Ig, 99 Lol p I-specific CD4 + clones generated in the presence of CD30-Fc, and 84 Lol p 1-specific CD4 + clones generated in the presence of anti-IL-4 Ab were compared for their ThI, ThO, or Th2 profiles . cell lines producing lower amounts of IL-4 and IL-5, but higher amounts (approximately a twofold increase) of IFN-y than did their corresponding control T cell lines (Fig. 4) . In contrast, when addition of the two CD30L-binding reagents was delayed to day 6 after Ag stimulation, T cell lines showed an IL-4 and IL-5 production almost comparable to that exhibited by their control lines . The same effect was seen for IFN-y production in Ag-specific T cell lines induced with late addition of CD30-Fc . However, blocking of CD30L by anti-CD30L mAb, even if delayed until day 6, was still effective in inducing Ag-specific T cell lines able to secrete higher amounts of IFN-y than did the corresponding control lines (Fig. 4) .
The results of this study indicate that CD30 plays an important role in both functional activity and development of Th2-like human CD4+ T cells . CD30, originally described as a marker of Hodgkin's and Reed-Sternberg cells of Hodgkin's lymphoma (18) and as an activation molecule of lymphoid cells that are detectable in scanty number around the lymphoid follicles in lymphoid tissues (19) , has been recently identified as a cytokine receptor belonging to the TNF receptor superfamily (11) . CD30 exists as membrane glycoprotein chains of 105 and 120 kD, derived from a 90-kD precursor and a 57-kD intracellular form (20) . The extracellular form of CD30 is proteolytically cleaved to produce an 88-kD soluble form of the molecule, which is released by CD30-expressing cells in vitro and in vivo (21) . In short-term cultures, CD30 expression is inducible on T and B cells transformed by virus (e.g., by human T cell lymphotropic virus types 1 and 2 or Epstein-Barr virus)
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Del Prete et al . (22) and on a small proportion of anti-CD3-stimulated CD45RO+ (memory) T cells, which exhibit enhanced B cell helper activity and produce both IFN-y and IL-5, thus resembling ThO cells (23, 24) . We have recently shown that, at the clonal level, membrane CD30 is preferentially expressed by human T cells producing Th2-type cytokines, e .g., Th2-and ThO-like cells (12, 25) . The discrepancy between our findings and those reported by Alzona et al. (24, 26) is only apparent and probably relates to the differences in the experimental approach used. It is likely that the cells expressing CD30 in response to the short-term and APCindependent polyclonal stimulation used by Alzona et al. represent precursors of T cells that predominantly develop into ThO cells . In their system, indeed, CD30+ T cells seem to be ThO-like cells able to provide optimal B helper cell activity (24) , but still lacking IL-4 production. In contrast, a clearer separation ofThl, ThO, and Th2 cells can be achieved in our model of Ag-specific T cell lines and clones, where repeated T cell stimulation in the presence of autologous APC makes IL-4 secretion easily detectable. The demonstration that CD30 triggering by anti-CD30 agonist Ab enhances Ag-induced proliferation and cytokine production by Th2 and ThO but not by Thl clones strongly supports our previous findings (12, 25) . Thus, it appears that CD30 is not only preferentially expressed on Th cells producing Th2-type cytokines, but it also acts as a costimulatory molecule whose cross-linking is able to promote both expansion and effector function of Th2-like cells .
The most interesting observation emerging from this study, however, is that, at least in vitro, CD30 costimulation also appears to play an important role in the development of Th2-like cells . First, the addition in bulk culture before cloning of agonist anti-CD30 Ab resulted in the development of higher proportions of Th2-like T cell clones than those obtained in parallel cultures stimulated with Ag and isotype control. More importantly, the blockade of CD30L-CD30 interaction by addition in bulk culture of anti-CD30L Ab or a soluble CD30-Fc fusion protein favored the development ofhigher numbers ofAg-specific Th cells showing the opposite (Thl-like) phenotype . Whereas the enrichment of Th2 cells induced by costimulation with anti-CD30 Ab may simply be due to a selection process that neglects Thl cells, the shift to the Thl profile resulting from blockade of CD30L-CD30 interaction more likely reflects a true change in the differentiation process ofAg-stimulated Th cells growing in culture . Only early blockade of CD30L-CD30 interaction was indeed effective in inhibiting the development ofa prevalent Th2 phenotype, whereas the later addition of either anti-CD30L Ab or soluble CD30-Fc had poor or no shifting effect . Thus, it is reasonable to suggest that the interaction of Ag-activated memory T cells expressing CD30 with CD30L+ APCs represents an effective costimulatory signal for their differentiation into T cell clones producing Th2-type cytokines . Whether different APC can differently express CD30L is still unclear . CD30L is expressed by a subset ofLPS-activated macrophages (16) and by the majority of B lymphocytes (15) ; no data regarding CD30 expression on dendritic cells are available .
The importance of costimulatory signals provided by APCs for optimal activation of T lymphocytes is well known. Several receptor-counterreceptor pairs mediate adhesion between APCs and T cells and deliver activating signals to T cells. The interaction of137 expressed on macrophages and dendritic cells with its CD28 receptor on T cells represents the best characterized example of this costimulation (27, 28) . The B7-CD28 interaction has recently been found to promote optimal proliferation of terminally differentiated ThI clones in both mice and humans (29) (30) (31) (32) (33) . More importantly, in Leishmania major-infected mice, in vivo blockade ofthe B7-CD28 interaction at the time ofparasite inoculation had a profound suppressive effect on the maturation of Th2 but not Thl cells, suggesting that important functional differences may underlie the costimulatory signals used by these two subsets of CD4 + T cells (34) . Accordingly, the blockade of CD30L-CD30 interaction might also interfere with a critical pathway required for in vitro Th2 development. This finding raises the question of whether such an interaction can inhibit the production of IL-12, which is considered the most important signal for the maturation of Thl cells (9, 10), or whether, alternatively, it may favor the early production of IL-4, which is required for the differentiation of both naive (7) and memory (8) CD4 + T cells References into mature Th2 effector populations . In this regard, it is of note that the blockade of CD30L-CD30 interaction was at least as effective in inhibiting Th2 development as the addition of an anti-IL-4 Ab. This suggests that CD30 triggering by CD30L-expressing APCs might contribute in some way to the early IL-4 production required for Th2 development. The kinetics of blockade of CD30-mediated effects may also be consistent with up-regulation of CD30 during T cell activation . Indeed, the addition of either anti-IL-4 or anti-CD30L Ab at the time ofAg stimulation resulted in a partial (between 31 and 40%) but consistent reduction of the proportion o£ CD30+ T cell blasts, as assessed by FRCS© analysis (data not shown) . Although preliminary, these findings suggest the existence of a complex network of interactions among CD30L expression, early IL-4 production, and regulation of CD30 expression in activated T cells that deserves more detailed investigation . Whatever the mechanism triggered by blockade of CD30-CD30L interaction is, the fact that CD30-Fc, a recombinant and stable analogue ofthe natural soluble CD30, is as effective as an anti-CD30L Ab in hampering the development of Th2-like cells allows us to consider this molecule as a potential tool in therapeutic strategies aimed to down-regulate undesired Th2 responses in vivo.
